Incyte Corporation · INCY · Next earnings

Incyte Corporation reports Tuesday, Feb 9, 2027

INCY reports before market open with consensus EPS at $1.86 and revenue at $1.55B. Last quarter: Incyte raises sales outlook as OPZELURA and pipeline advance

Reports Before market open96 days awayDate estimated Healthcare

What the street expects

Consensus for the coming report
Consensus EPS $1.86 Calendar consensus
Consensus revenue $1.55B Calendar consensus
Report date Feb 9, 2027 Tuesday, date estimated
Session Before market open 96 days away

Where INCY left off: FY2026 Q3

Full report

Incyte raises sales outlook as OPZELURA and pipeline advance

EPS surprise +8.4% Reported $-3.60 vs $-3.93
Revenue surprise +6.3% Reported $1.56B vs $1.46B
Stock move -0.1% Event window
Subsequent drift 0.0% Up to 20 sessions

Full-year net-sales guidance was raised to $5.21-$5.30 billion; expense guidance was maintained.

What to watch on the call

Carried forward from the last transcript

Risks management flagged

  • Execution risk in enrolling and completing multiple Phase III trials on time.
  • Regulatory timing and potential setbacks for povorcitinib, MONJUVI, and tafasitamab.
  • Pricing pressure despite benefits from the CMS line-extension settlement.
  • Competition in KRAS G12D inhibitors and CALR antibodies.

Questions analysts left open

  • Timing and data readouts for the 989 frontline myelofibrosis study.
  • Definition of prior JAK-inhibitor exposure in second-line myelofibrosis trials.
  • The delay of the axatilimab first-line readout to Q1 2027.
  • The rationale for stopping CDK2 Phase III enrollment.
  • Labeling scenarios and market potential for povorcitinib in hidradenitis suppurativa.

Ask FN2 about INCY next report

Transcript, numbers and history already loaded
What should I watch for in INCY's next earnings report?How did INCY guide last quarter, and is consensus above or below that?Give me the bull and bear case going into INCY earnings.

Free account. Your question opens in FN2 with this report's transcript and numbers attached.

Get the INCY recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Recent INCY quarters

All INCY earnings
-0.1%FY2026 Q3+9.3%FY2026 Q2+2.1%FY2026 Q1-8.2%FY2025 Q4

Sources

  1. FN2 corporate events calendar, resolved from the earnings calendar feed
  2. FN2 earnings calendar analyst consensus
  3. Earnings call transcript analysis, FY2026 Q3

Methodology

The report date comes from FN2's resolved corporate-events calendar and is marked estimated until the company confirms it. Consensus figures are the calendar's latest analyst estimates for the fiscal period and are not an FN2 forecast.

Risks and open questions are carried forward verbatim from FN2's structured analysis of the previous earnings call. Missing values stay missing and are never estimated.

By FN2 Research · Updated . For educational purposes only; not investment advice.